The potent synthetic androgens, dimethandrolone (7α,11β-dimethyl-19-nortestosterone) and 11β-methyl-19-nortestosterone, do not require 5α-reduction to exert their maximal androgenic effects

[1]  A. Matsumoto,et al.  Long-term effects of dimethandrolone 17β-undecanoate and 11β-methyl-19-nortestosterone 17β-dodecylcarbonate on body composition, bone mineral density, serum gonadotropins, and androgenic/anabolic activity in castrated male rats. , 2011, Journal of andrology.

[2]  A. Matsumoto,et al.  Long-Term Effects of Dimethandrolone 17Beta-Undecanoate (DMAU) and 11Beta-Methyl-19-Nortestosterone 17Beta-Dodecylcarbonate (11Beta-MNTDC) on Body Composition, Bone Mineral Density (BMD), Serum Gonadotropins, and Androgenic/Anabolic Activity in Castrated Male Rats. , 2009 .

[3]  J. Reel,et al.  Dimethandrolone (7α,11β-dimethyl-19-nortestosterone) and 11β-methyl-19-nortestosterone are not converted to aromatic A-ring products in the presence of recombinant human aromatase , 2008, The Journal of Steroid Biochemistry and Molecular Biology.

[4]  J. Reel,et al.  Dimethandrolone undecanoate: a new potent orally active androgen with progestational activity. , 2006, Endocrinology.

[5]  J. Dalton,et al.  Chemistry and structural biology of androgen receptor. , 2005, Chemical reviews.

[6]  D. Tindall,et al.  Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia. , 2004, The Journal of urology.

[7]  M. Oettel.  The endocrine pharmacology of testosterone therapy in men , 2004, Naturwissenschaften.

[8]  M. Byrne,et al.  Testosterone replacement therapy in male hypogonadism , 2003, Journal of endocrinological investigation.

[9]  Culley Carson,et al.  The role of dihydrotestosterone in benign prostatic hyperplasia. , 2003, Urology.

[10]  J. Reel,et al.  CDB-4124 and its putative monodemethylated metabolite, CDB-4453, are potent antiprogestins with reduced antiglucocorticoid activity: in vitro comparison to mifepristone and CDB-2914 , 2002, Molecular and Cellular Endocrinology.

[11]  M. K. James,et al.  Unique preclinical characteristics of GG745, a potent dual inhibitor of 5AR. , 1997, The Journal of pharmacology and experimental therapeutics.

[12]  C. Bardin,et al.  Different patterns of metabolism determine the relative anabolic activity of 19-norandrogens , 1995, The Journal of Steroid Biochemistry and Molecular Biology.

[13]  Y. Ito,et al.  Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. , 1994, Endocrine reviews.

[14]  C. Bardin,et al.  The biological activity of 7 alpha-methyl-19-nortestosterone is not amplified in male reproductive tract as is that of testosterone. , 1992, Endocrinology.

[15]  C. Bardin,et al.  Radioimmunoassay of 7α-methyl-19-nortestosterone and investigation of its pharmacokinetics in animals , 1990, The Journal of Steroid Biochemistry and Molecular Biology.

[16]  R. G. Christiansen,et al.  Antiandrogenic steroidal sulfonylpyrazoles. , 1990, Journal of medicinal chemistry.

[17]  C. Monder,et al.  In Vitro Metabolism of 7α-Methyl-19-Nortestosterone by Rat Liver, Prostate, and Epididymis , 1988 .

[18]  W F Raub,et al.  The PROPHET system and resource sharing. , 1974, Federation proceedings.

[19]  R. K. Meyer,et al.  Myotrophic Activity of 19-Nortestosterone and Other Steroids Determined by Modified Levator Ani Muscle Method.∗ , 1953, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.